AHK-Cu: One In Vitro Paper From 2007, and Its Own Apoptosis Finding Was Not Significant

AHK-Cu is sold for hair growth on the strength of a single 2007 paper that studied cells in a dish. PubMed returns one record for the compound. ClinicalTrials.gov returns zero. That is the entire evidence base.

Everything below follows from those two counts. Identity and vendor listings sit on the AHK-Cu compound page, within the skin and anti-aging peptides category, and the comparison that matters most is with the copper peptide one amino acid away.

How much human evidence exists for AHK-Cu?

None. A PubMed search for "AHK-Cu" returns one result — Pyo, Yoo, Won and colleagues, Archives of Pharmacal Research 2007;30(7):834–839, PMID 17703734 — and that study used cultured human dermal papilla cells and excised hair follicles, with no living human subject anywhere in it. ClinicalTrials.gov returns totalCount = 0. That is the complete evidence base for a compound sold in ninety-plus vendor listings for hair growth.

The gap between one in vitro paper and ninety-plus commercial listings is the single most important fact about this compound, and it is not a matter of interpretation. It is two database queries, both of which anyone can repeat.

What did the 2007 study actually find?

Pyo and colleagues cultured human dermal papilla cells and excised human hair follicles with a tripeptide-copper complex at 10⁻¹² to 10⁻⁹ molar — picomolar to nanomolar concentrations in culture medium — and no living human subject appears anywhere in the study. Its own stated negative is easy to miss: the reduction in apoptotic dermal papilla cells "was not statistically significant." That is the paper the entire market rests on.

Because this is the whole literature, it is worth reading carefully rather than summarising.

A study reporting its own null result is doing science properly. The problem is not the paper. The problem is what nineteen years of marketing has made of it.

Does "human hair growth" in the title mean humans?

No. The title is "The effect of tripeptide-copper complex on human hair growth in vitro," and the last two words carry the whole meaning. The material was human — cultured dermal papilla cells and excised follicles — but the experiment happened in a dish, not on a head. Vendors quote "human hair growth" and drop the two words that follow, which converts a screening result into a clinical claim it never made.

The trap is unusually clean, because the quoted fragment is verbatim. Nothing has been invented; a qualifier has been deleted. That is why the claim survives casual fact-checking: search the phrase, find the paper, see the word "human," and stop reading one word early.

Why doesn't a follicle in a dish predict a scalp?

Because excised follicle culture removes everything that determines whether a hair grows on a person: blood supply, systemic hormones, immune surveillance, sebaceous function, and the androgen signalling that drives pattern hair loss in the first place. It is a legitimate screening model and it is not a clinical test. Picomolar to nanomolar concentrations in culture medium also bear no defined relationship to what any AHK-Cu preparation delivers to a dermal papilla.

Excised follicle culture earns its place in dermatology research. A compound that maintains follicles in medium has passed a screening step, which is a reason to run the next experiment rather than a reason to sell a product.

The concentration point is the sharper of the two. Cells in a dish are bathed in a known concentration; nobody has measured what concentration reaches a human follicle from any AHK-Cu preparation, topical or injected, because no human pharmacokinetic study of this compound exists. The dose-response curve in the paper therefore cannot be mapped onto anything a buyer would apply.

What is AHK-Cu, and how does it differ from GHK-Cu chemically?

AHK-Cu is GHK with one substitution: alanine replaces glycine at position 1. That is a single CH₂ group, and the free peptides differ by exactly that — 340.38 for GHK against 354.41 for AHK. The copper complexes behave the same way. AHK's free tripeptide is PubChem CID 7408502, CAS 126828-32-8; the monohydrochloride of the copper complex is CID 171382526, CAS 682809-81-0, at 452.39.

One methylene group is the entire structural difference between the compound with a substantial in vitro literature and the compound with one paper. That should be a caution against reasoning from structure to evidence: the molecules are near-identical and their research records are not. GHK-Cu is the better-documented of the two by a wide margin.

Which molecular weight goes with CAS 682809-81-0?

452.39, the hydrochloride salt of the copper complex. The uncharged complex would be C₁₅H₂₄CuN₆O₄ at approximately 415.94, so a vendor quoting "AHK-Cu, MW 415.9, CAS 682809-81-0" has mismatched the salt form to the mass — a 36 Da error, about 8%, straight into a dose calculation. The same copper-versus-copper-free problem as GHK-Cu applies on top of it, at a gap of roughly 98 Da.

An 8% mass error is not catastrophic on its own, but it is a reliable signal about the vendor: a specification block that pairs a CAS number with the wrong molecular weight was assembled by copying, not by checking.

The copper question is the larger one. The mass gap between free AHK at 354.41 and the copper complex is roughly 98 Da in the hydrochloride form. HPLC purity testing measures peak area by hydrophobicity and detects no metals whatsoever, so a vial of copper-free AHK peptide returns an excellent purity number. Only mass spectrometry, or elemental analysis for copper, can tell you which you have. The pattern is catalogued in red flags in peptide certificates of analysis.

How does AHK-Cu compare with GHK-Cu on evidence?

GHK-Cu's evidence base is thin and AHK-Cu's is a rounding error next to it. GHK-Cu has a substantial in vitro literature, one randomised controlled trial with null objective endpoints, three ClinicalTrials.gov records and 736 lab tests on this platform. AHK-Cu has one PubMed record, zero randomised trials, zero registered studies and 25 lab tests. The two are marketed as a pair, and no head-to-head human comparison exists.

The pairing usually assigns AHK-Cu to hair and GHK-Cu to skin. That division of labour comes from the 2007 paper's subject matter, not from any comparative human study, and nobody has tested them head to head in a person. Both appear in the follicle literature covered in peptides for hair growth; the third compound in this cluster, SNAP-8, fails on molecular size rather than on record count.

How much copper does an AHK-Cu dose deliver?

AHK-Cu is roughly 14% elemental copper by mass in the hydrochloride form — our calculation from the verified molecular weights. Milligram doses therefore deliver hundreds of micrograms of copper, a substantial fraction of the 900 µg/day adult RDA, administered parenterally in someone whose hepatic copper handling has not been assessed. Copper leaves the body primarily through biliary excretion, and no human pharmacokinetic data exists for this compound at all.

The same considerations apply as for GHK-Cu, with less data behind them. Oral copper absorption is regulated by the intestine; injection bypasses that regulation entirely without providing any alternative clearance route. The adult copper RDA is 900 µg/day and the Tolerable Upper Intake Level is 10,000 µg/day, per the NIH Office of Dietary Supplements, which also notes that "chronic exposure to high levels of copper can result in liver damage and gastrointestinal symptoms."

People with Wilson's disease — an autosomal recessive defect in copper clearance — are at particular risk and frequently do not know they carry it. Get liver function and copper status checked before any copper-containing injectable if there is a personal or family history of liver or unexplained neurological disease.

None of this is a claim that AHK-Cu causes copper toxicity. It is a statement that a metal is being administered, that its only meaningful exit route is bile, and that no human pharmacokinetic data exists for this compound at all.

Has any regulator evaluated AHK-Cu?

No. AHK-Cu does not appear anywhere on FDA's compounding pages — not in the active Category 2 list, not in the "nominated but withdrawn" table where GHK-Cu does appear, and not on the 503A or 503B bulks lists. It was never nominated, so FDA has never evaluated it. That absence is not clearance: without a USP monograph or status as a component of an approved drug, AHK-Cu is an unapproved new drug in the United States.

The distinction matters because absence gets read as permission. GHK-Cu is on an FDA page with published safety language attached; AHK-Cu is on none, which means no reviewer has ever looked at it. Satisfying none of the three statutory routes for 503A compounding is a stronger statement than being reviewed and passed over.

On WADA: neither AHK, AHK-Cu, copper peptide nor copper appears anywhere in the 2026 Prohibited List. The S0 catch-all applies to pharmacological substances lacking approval for human therapeutic use, and status here is genuinely ambiguous — a topical cosmetic is a weak S0 candidate; an injected preparation is a much stronger one. We are not asserting either way. The wider sequence of determinations is in our FDA peptide regulation timeline.

Why is AHK-Cu's purity average the lowest on the platform?

One test. The Purity Index records AHK-Cu at 97.38% average across 25 HPLC tests (verified May 2026), from Vanguard, ILS, Kovera, Janoshik and Freedom Diagnostics, across 221 verified vendors — and one vendor's June 2026 test returned 50.63% purity with a 10.6% quantity shortfall. The remaining tests cluster above 99%. On a 25-test dataset, that single outlier drags the category average down by nearly two percentage points.

A single result at 50.63% is not a marginal failure. It means roughly half the material in that vial was something other than the labelled compound, and the accompanying 10.6% quantity shortfall means there was less of it than the label claimed — the problem set out in why 10 mg isn't 10 mg.

The arithmetic is itself a useful illustration of why thin test coverage is a risk in its own right. With 736 tests, as GHK-Cu has, an outlier is visible as an outlier. With 25, it moves the headline number. Read individual vendor results rather than the category average whenever the test count is this low.

AHK-Cu price data shows just 9 shops in stock, median $0.70/mg, lowest $0.38/mg on a 100 mg vial at $38.00 (verified 9 August 2026). Those figures exclude shipping, taxes and customs, coupon codes, bulk tiers, multi-vial kits and account-gated pricing. Nine shops in stock against 221 known vendors is a thin, illiquid market — which is consistent with a compound whose demand is driven by a single 2007 paper.

Peptigrity tracks 530 shops and 11,852 independent lab tests across 118 peptides, with 1,283 community reviews (verified August 2026). Trust scores weight community reviews and independently verified HPLC purity equally, at 50% each. Certificates sit in the lab test database and vendor rankings in community-verified shop reviews.

How do you verify an AHK-Cu vial?

Mass spectrometry first, because it is the only routine test that distinguishes the 452.39 Da copper complex in its hydrochloride form from the 354.41 Da free peptide. HPLC purity establishes homogeneity and detects no metals whatsoever, so a vial of copper-free AHK returns an excellent number. Ask which salt form the stated mass refers to, and treat an unstated salt form as an unanswered 8% question.

Two of those five checks are routinely available and three are not, which is the practical position for anyone buying this compound. What mass spectrometry for peptides resolves in one reading, a purity certificate leaves open.

Which AHK-Cu claims survive the evidence?

None of the nine. Every claim the compound is marketed on either has no human data behind it, misquotes the one paper, or contradicts a verifiable fact — "clinically proven" is false against ClinicalTrials.gov totalCount = 0, the apoptosis result was "not statistically significant," purity testing detects no metals, and a quoted MW of 415.9 does not belong with CAS 682809-81-0. FDA has never assessed it.

Three of those verdicts are not judgements about evidence strength at all. "Misquoted," "Mismatched" and "Never assessed" are factual corrections, and they will still be true whichever way the efficacy question eventually resolves.

Frequently Asked Questions

Is AHK-Cu proven for hair growth?

No. PubMed returns a single record for AHK-Cu: a 2007 study in cultured human dermal papilla cells and excised hair follicles, at picomolar to nanomolar concentrations. ClinicalTrials.gov returns zero registered studies. There is no human evidence of any kind.

Doesn't the study title say "human hair growth"?

It says "human hair growth in vitro." The material was human — cultured cells and excised follicles — but no living person was studied. Marketing copy routinely quotes the first three words and drops the qualifier.

How is AHK-Cu different from GHK-Cu?

One amino acid: alanine replaces glycine at position 1, a difference of a single CH₂ group. GHK-Cu has a substantial in vitro literature and one randomised trial, which found no objective improvement. AHK-Cu has one paper.

Why is AHK-Cu's purity average so low?

A single test at 50.63% purity, from a vendor in June 2026, against a dataset of only 25 tests. The rest cluster above 99%. A thin test base means one bad result moves the average — which is a reason to look at individual vendor results rather than the category number.

Can testing confirm the copper is present?

Not by HPLC, which measures peak area and detects no metals. Mass spectrometry distinguishes the 452.39 Da copper complex from the 354.41 Da free peptide immediately. Elemental analysis measures copper content directly, and we have not seen it offered by any vendor in this market.

Has FDA evaluated AHK-Cu?

No. It does not appear on any FDA compounding list — unlike GHK-Cu, which is in the "nominated but withdrawn" table with published safety language. AHK-Cu was never nominated, so it has never been assessed.

The trial that would settle this

The trial that would settle AHK-Cu is the one nobody has run: a phase 1 safety and pharmacokinetic study, because zero human studies of any kind exist. Beyond that, a randomised, vehicle-controlled, blinded trial with trichoscopic hair counts rather than investigator impression, against minoxidil or finasteride, over six months or more, with serum copper, ceruloplasmin and liver function monitored throughout. None of that is a high bar; it is the ordinary first step.

In nineteen years nobody has taken that first step.

Where this leaves AHK-Cu

AHK-Cu has the thinnest evidence base on this platform, and the gap between that and its market presence is the point. There is one paper, published in 2007, on cells and excised follicles in culture medium at picomolar concentrations, with no living human involved and a headline apoptosis finding that did not reach statistical significance. In the nineteen years since, nobody has registered a trial.

No regulator has evaluated the compound, and no human pharmacokinetic study has been published. Against that: two hundred and twenty-one vendors list it, it is sold for injection as well as topical use, and it delivers a metal that leaves the body only through bile into people whose liver function nobody has checked.

The compound might work. A dermal papilla is a reasonable target and copper peptides are not an absurd idea. But nineteen years is a long time for a marketed product to have exactly one supporting publication with "in vitro" in its title.

Browse the skin and anti-aging peptides category, or our complete peptide guide with 118 compounds (verified August 2026). Compare shops through independent lab tests and community-verified shop reviews.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.